Published in Hepatitis Weekly, March 4th, 2002
Because the combination is expensive and does not significantly reduce viral load over other current hepatitis C virus (HCV) treatment regimens, the researchers would not recommend it for supplanting combination therapy that includes ribavirin, based on the results of their large-scale double-blind, placebo-controlled study.
The efficacy of amantadine/combination therapy for treating hepatitis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.